摘要
目的:探讨DC-CIK细胞在中晚期非小细胞肺癌(NSCLC)患者中的临床治疗效果。方法:80例中晚期NSCLC患者按治疗方法分为化疗组(A组)和DC-CIK联合化疗组(B组),各40例;A组采用常规化疗方案铂类联合盐酸吉西他滨4个疗程;B组同时实施DCCIK细胞治疗。4个月时比较两组治疗效果及毒副作用。随访1年时比较无疾病进展期和死亡率。结果:B组CR8例,PR9例,SD17例,PD6例,A组CR6例,PR7例,SD15例,PD12例。B组临床有效率、临床获益率显著高于A组(P<0.05);两组间骨髓抑制、肝肾功能损害无显著差异。B组胃肠道反应、疲乏乏力及食欲减退显著低于A组(P<0.05)。随访1年B组无疾病进展期(PFS)7.4月,A组PFS为6.1月(P<0.05)。两组间1年死亡率无显著差异。结论:NSCLC中晚期在放、化疗,靶向药物综合治疗的过程中尽早应用DCCIK,能够提高临床疗效,降低治疗毒副反应,提高机体免疫力,改善患者生存质量。
Objective： To investigate the clinical therapeutic effect of DC-CIK cells in patients with middle and advanced non small cell lung cancer（NSCLC）.Methods： 80 cases of middle and advanced NSCLC patients according to treatment methods are divided into chemotherapy group（group A） and DC-CIK combined with chemotherapy group（group B）,40 cases in each; group A by routine chemotherapy platinum class hydrochloride combined with gemcitabine four courses of treatment; group B at the same time the implementation of DC-CIK cell treatment.The therapeutic effect and side effects of two groups were compared at 4 months.No disease progression and mortality were compared at 1 years of follow-up.Results： Group B,CR8 cases,PR9 cases,SD17 cases,PD 6 cases,group A,CR6 cases,PR7 cases,SD15 cases,PD12 cases.The clinical efficiency and clinical benefit rate of group B was significantly higher than that of group A（P〈0.05）.There was no significant difference in bone marrow suppression,liver and renal function between the two groups.Group A（P〈0.05） was significantly lower than the group B（P〈0.05） in the gastrointestinal reaction,fatigue and loss of appetite.The patients were followed up for 1 years without disease progression（PFS） 7.4 months,group A,PFS was 6.1 months（P〈0.05）.There was no significant difference in 1 year mortality rate between the two groups.Conclusion： Early application of DC-CIK can improve the clinical efficacy,reduce treatment toxicity,improve immunity and the quality of life of patients combined with chemotherapy,radiotherapy,and targeted drugs in the treatment of Middle and advanced NSCLC.
出处
《中国医药导刊》
2016年第4期335-336,338,共3页
Chinese Journal of Medicinal Guide
关键词
DC-CIK细胞
化疗
中晚期非小细胞肺癌
治疗效果
DC-CIK cells
Chemotherapy
Middle and Advanced non small cell lung cancer
Therapeutic effect
